Oura reaches $11 billion valuation with new $900 million fundraise

Oura has successfully closed a Series E funding round, raising over $900 million led by Fidelity Management & Research Company, which values the company at $11 billion and brings total funding to approximately $1.5 billion. This significant investment follows robust financial performance, with over $500 million in revenue in 2024 (doubling year-over-year) and projected sales of $1 billion this year, alongside over 5.5 million Oura Rings sold. The capital will accelerate innovation and global expansion, as Oura intensifies its focus on preventive health wearables through new features like Health Panels for blood testing and a partnership with Dexcom for glucose monitoring, positioning it competitively against both specialized and general wearable device manufacturers.

Analysis

Oura secured over $900 million in a Series E funding round, led by Fidelity Management & Research Company, elevating its valuation to $11 billion and bringing total funding to approximately $1.5 billion. This capital injection follows robust financial performance, with 2024 revenue exceeding $500 million, more than double the prior year, and a projected $1 billion in sales for 2025. Product adoption is strong, with over 5.5 million Oura Rings sold since launch, a significant increase from 2.5 million reported in June 2024.

CEO Tom Hale stated the investment will accelerate innovation and global expansion, aiming to set new standards in preventive health wearables. Oura, ranked No. 23 on CNBC's 2025 Disruptor 50 List, is intensifying its competitive stance against specialized smart ring makers and broader fitness/general wearable device manufacturers like Garmin (GRMN) and Apple (AAPL). This strategic positioning indicates a clear intent to capture a larger share of the health tech market.

Oura's expansion into advanced health monitoring is evident through new features like Health Panels, enabling users to view blood test results for up to 50 biomarkers directly in the Oura App, supported by an AI-powered Advisor. The partnership with Dexcom (DXCM) to integrate glucose data with Oura's biometrics further enhances its offering in proactive health management, underscoring a strategic pivot towards comprehensive health insights.

Key Decisions for Investors

• Monitor Oura's private market valuation trajectory and potential for a future public offering, given its significant growth and market disruption in the health tech sector.
• Evaluate the competitive landscape, particularly how Oura's advanced health features and partnerships, such as with Dexcom (DXCM), impact established wearable players like Garmin (GRMN) and Apple (AAPL).
• Assess the long-term viability of Oura's AI-powered preventive health ecosystem and its ability to sustain rapid revenue growth and user adoption in a competitive and evolving market.